Abcam, ab250663, Anti-SIKE1 antibody [EPR14692] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal SIKE1 antibody. Carrier free. Suitable for IP, WB, IHC-P and reacts with Mouse, Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR14692,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Human,
Applications:IHC-P, IP, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab250663 is the carrier-free version of
ab183509
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
SIKE1 also known as Squamous Cell Carcinoma Antigen Recognized by T-cells 3 (SART3) is a protein with a molecular weight of approximately 24 kDa. It inhibits the kinase activity of Tank-Binding Kinase 1 (TBK1) and IκB kinase ε (IKKε) which are critical for the induction of type I interferons and other cytokines in response to viral infections. SIKE1 is primarily expressed in various tissues including the brain and liver though expression levels may vary depending on cellular context.
Biological function summary
SIKE1 interacts with signaling pathways to modulate immune responses. As a negative regulator of the interferon signaling pathway it forms complexes with TBK1/IKKε to suppress excessive immune activation preventing potential tissue damage. By efficiently regulating kinase activity SIKE1 helps maintain balance in immune signaling ensuring proper immune defense while avoiding overactivation.
Pathways
The involvement of SIKE1 extends to the toll-like receptor (TLR) and retinoic acid-inducible gene I (RIG-I)-like receptor signaling pathways. These pathways play essential roles in detecting and responding to viral pathogens. SIKE1 modulates the activity of TBK1 and IKKε which are central to the aforementioned pathways impacting downstream molecules like IRF3 and NF-kB that drive interferon production and inflammatory responses.
SiKE1's regulatory role relates to conditions characterized by dysregulated immune responses. For instance in viral infections where excessive interferon production occurs SIKE1 can mitigate potential tissue damage by dampening cytokine output. It is also studied in auto-inflammatory disorders where control of cytokine production is important for managing disease severity. Its connection to TBK1 and IKKε further implicates SIKE1 in the context of these immune-related conditions as these kinases are targets for therapeutic intervention in disorders related to immune dysregulation.